Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates enhanced tumor targeting and apoptosis in breast cancer models using dual-drug YIGSR liposomes, suggesting potential for targeted anticancer therapy.
Targeted liposomes represent an excellent drug delivery system for enhancing therapeutic effects. In this study, a novel YIGSR-modified liposomal formulation co-encapsulating two antitumor drugs, doxorubicin (DOX) and ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F), was developed to achieve good targeting capability and antitumor efficacy.The physicochemical properties of YIGSR-(DOX-5F)-LP were characterized and the liposomes exhibited a uniform particle size, high encapsulation efficiency and a sustained release profile. In vitro cytotoxicity assays indicated that YIGSR-(DOX-5F)-LP exerted the strongest cytotoxicity and highest levels of cellular apoptosis in DOX-sensitive MCF-7 cells. Its targeting ability was evaluated by in vitro cellular uptake assays in MCF-7 cells and in vivo biodistribution studies in tumor-bearing nude mice, respectively. The results showed that compared with non-targeted co-drug-loaded liposomes (DOX-5F-LP), YIGSR-(DOX-5F)-LP achieved higher cellular uptake in MCF-7 cells and exhibited greater accumulation in tumor tissues relative to other major organs. In conclusion, the YIGSR-(DOX-5F)-LP displayed prominent targeting activity toward MCF-7 cells both in vitro and in vivo, demonstrating a great potential for further preclinical investigation.
No takes yet. Share an insight, caveat, or question.
Duan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: